In two different NASH mouse obesity models, an atherogenic diet model and ob/ob mice, chronic treatment with liraglutide reduced body weight, lowered steatosis scores and inhibited fibrosis (through a decreased col1a1) (17). The gene discussed is COL1A1; the disease is steatosis.